Your browser doesn't support javascript.
loading
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Nilsson, Monique B; Giri, Uma; Gudikote, Jayanthi; Tang, Ximing; Lu, Wei; Tran, Hai; Fan, Youhong; Koo, Andrew; Diao, Lixia; Tong, Pan; Wang, Jing; Herbst, Roy; Johnson, Bruce E; Ryan, Andy; Webster, Alan; Rowe, Philip; Wistuba, Ignacio I; Heymach, John V.
Afiliação
  • Nilsson MB; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Giri U; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gudikote J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tang X; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lu W; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tran H; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fan Y; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Koo A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Diao L; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tong P; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Herbst R; Section of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut.
  • Johnson BE; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts. Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
  • Ryan A; Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Webster A; AstraZeneca, Cambridge, United Kingdom.
  • Rowe P; AstraZeneca, Cambridge, United Kingdom.
  • Wistuba II; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jheymach@mdanderson.org.
Clin Cancer Res ; 22(8): 1940-50, 2016 Apr 15.
Article em En | MEDLINE | ID: mdl-26578684
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Quinazolinas / Carcinoma Pulmonar de Células não Pequenas / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Fator A de Crescimento do Endotélio Vascular / Inibidores de Proteínas Quinases / Serina-Treonina Quinases TOR / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Quinazolinas / Carcinoma Pulmonar de Células não Pequenas / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Fator A de Crescimento do Endotélio Vascular / Inibidores de Proteínas Quinases / Serina-Treonina Quinases TOR / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Ano de publicação: 2016 Tipo de documento: Article